Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(13%)
Results Posted
20%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
2
25%
Ph phase_1
6
75%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
6(75.0%)
Phase 2Efficacy & side effects
2(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Withdrawn1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (75.0%)
Phase 22 (25.0%)

Trials by Status

completed563%
withdrawn113%
active_not_recruiting113%
terminated113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982
completedphase_1

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

NCT03431948
terminatedphase_1

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

NCT02253992
completedphase_1

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

NCT02534506
completedphase_1

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

NCT02252263
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02451982Phase 2

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Active Not Recruiting
NCT03431948Phase 1

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Completed
NCT02253992Phase 1

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Terminated
NCT02534506Phase 1

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Completed
NCT02252263Phase 1

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Completed
NCT02110082Phase 1

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Completed
NCT01775631Phase 1

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Completed
NCT02420938Phase 2

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8